Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep 8:4:100082.
doi: 10.1016/j.gloepi.2022.100082. eCollection 2022 Dec.

Relapse-free survival in Sudanese women with non-metastatic breast cancer

Affiliations

Relapse-free survival in Sudanese women with non-metastatic breast cancer

Hiba Faroug Muddather et al. Glob Epidemiol. .

Abstract

Background: Breast cancer (BC) is the most frequently diagnosed cancer and a major cause of cancer mortality in Sudan. However, there is lack of data related to BC relapse. Therefore, this study was undertaken to estimate the 5-year relapse free survival (RFS) rate and factors related to BC relapse in Sudanese women with non-metastatic BC.

Methods: Data of BC women with BC diagnosed and treated at the National Cancer Institute-University of Gezira during 2012 were retrieved from medical records. The cases were followed-up through hospital records and telephone contact. Survival functions were calculated using Kaplan-Meier method and compared by log-rank test. The prognostic factors were tested using univariate and multivariable Cox regression analyses.

Results: We included 168 women with median age of 45 years (range, 22-83 years). 53.5%of women had stage III at time of diagnosis, whereas 4.2% and 42.3% of women presented with stage I and stage II, respectively. At the end of 5 years follow-up, with median follow-up period of 64 months, 94 (56.0%) women were alive in remission, 11 (6.5%) were alive with BC relapse, 49 (29.2%) were dead, and survival status was unknown in 14 (8.3%) women. Most of the occurred relapses were distant relapses. The 5-year RFS was 59%. The independent predictors of relapse were: larger primary tumor size (HR:1.84, 95% CI: 1.54-5.48, p=0.018); involved axillary lymph nodes with tumour (HR: 2.91, 95% CI: 1.53-7.91, p=0.001); not receiving adjuvant radiotherapy (HR: 2.2, 95% CI: 1.22-3.95, p=0.009); and not receiving hormone therapy (HR: 1.67, 95% CI: 1.01-2.76, p= 0.046).

Conclusion: We found a high risk of BC relapse in our resource-constrained settings. Advanced stages, not receiving adjuvant radiotherapy, and not receiving adjuvant hormone therapy were independent predictors associated with worse 5-year RFS. Therefore, enhancing the early diagnosis of BC and improving timely access to appropriate treatments represent key approaches to achieving better treatment outcomes.

Keywords: Breast cancer treatment; Breast neoplasms; Cancer recurrence; Disease-free survival; Low-income countries; Prognostic factors.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
The status of patients with breast cancer at the end of 5-year follow-up (N = 168).
Fig. 2
Fig. 2
Relapse-free survival of breast cancer patients (n = 168). A: Cumulative relapse-free survival curve. B: Relapse-free survival according to lymph node involvement. C: Relapse-free survival according to clinical stage. D: Relapse-free survival according to the type of surgery. E: Relapse-free survival according to radiotherapy. F: Relapse-free survival according to hormone therapy.

Similar articles

Cited by

References

    1. Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. - PubMed
    1. DeSantis C.E., Bray F., Ferlay J., Lortet-Tieulent J., Anderson B.O., Jemal A. International variation in female breast cancer incidence and mortality rates. Cancer Epidemiol Biomarkers Prev. 2015;24(10):1495–1506. - PubMed
    1. Elhassan M.M.A. Access to treatment for gynaecological malignancies in Sudan. S Afr J Gynaecol Oncol. 2018;10(2):21–23.
    1. Elgaili E.M., Abuidris D.O., Rahman M., Michalek A.M., Mohammed S.I. Breast cancer burden in Central Sudan. Int J Womens Health. 2010;2:77–82. - PMC - PubMed
    1. Mariani-Costantini R., Elhassan M.M.A., Aceto G.M., Mohamedani A.A., Awadelkarim K.D. Epidemiology, pathology, management and open challenges of breast cancer in Central Sudan: a prototypical limited resource African setting. Breast Cancer-From Biol Med. 2017 doi: 10.5772/67175. - DOI

LinkOut - more resources